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Abstract
Background: Lymphocyte Function-Associated Antigen-1 (LFA-1; CD18/CD11a) is one of the main adhesion molecules
used by immune cells to infiltrate the liver under inflammatory conditions. Recently, the expression of this integrin has
also been reported on several solid tumors, including colorectal cancer. However, its functional role in the metastatic
progression to the liver remains unknown. Using in vitro assays and an experimental orthotopic in vivo model of liver
metastasis, we aimed to elucidate the role of tumor LFA-1 in the metastatic progression by means of the partial
depletion of the β2 subunit of LFA-1, required for integrin activation, firm adhesion and signaling.
Methods: To do so, we evaluated the effects of β2 reduction on the murine colon carcinoma C26 cell line on
their pro-metastatic features in vitro and their metastatic potential in vivo in a mouse model of colon carcinoma
metastasis to the liver.
Results: The reduction in β2 integrin expression correlated with a slower proliferation, and a reduced adhesion
and migration of C26 cells in an in vitro setting. Additionally, tumor cells with a reduced in β2 integrin expression
were unable to activate the liver sinusoidal endothelial cells (LSECs). This resulted in a recovery of the cytotoxic
potential of liver lymphocytes which is compromised by LSECs activated by C26 cells. This was related to the
abrogation of RNA expression of inflammatory and angiogenic cytokines by C26 cells after their activation with
sICAM-1, the main ligand of β2αL. Furthermore, in vivo tumor cell retention and metastasis were profoundly reduced,
along with a decrease in the recruitment and infiltration of myeloid derived suppressor cells (MDSCs) and lymphocytes
to the liver.
Conclusion: Taken together, our findings uncovered the modulatory role for the tumor β2 subunit of the LFA-1 integrin
in the metastatic progression of colorectal cancer to the liver by impairing activation of liver endothelium and thus, the
local immune response in the liver. Besides, this integrin also showed to be critical in vivo for tumor cell retention,
cytokine release, leukocyte recruitment and metastasis development. These data support a therapeutical potential of
the integrin LFA-1 as a target for the treatment of colorectal liver metastasis.
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Background
Hepatic metastasis still remains as one of the most life-
challenging aspects in the dissemination of cancer. The
early retention of the tumor cells into a secondary organ,
which leads to metastasis, might be due to the up-
regulation in the expression of adhesion molecules and/
or changes in their distribution [1, 2], enabling the adhe-
sion and infiltration of metastasizing cancer cells in the
target organ [1, 3]. In fact, the reciprocal interaction be-
tween liver sinusoidal endothelial cells (LSECs) and can-
cer cells through these adhesion molecules also triggers
an acute inflammatory response [2, 4] which helps in the
creation of a suitable microenvironment favoring the
metastatic progression.
Lymphocyte Function Associated Antigen (LFA)-1
(CD11a/CD18 or αLβ2) is a heterodimeric protein of the
integrin family expressed on the surface of nearly all leu-
kocytes [5] and recently described on a variety of tumor
cells [1, 6, 7] including colorectal cancer cells [8, 9].
LFA-1 is the main ligand for intercellular adhesion mol-
ecule (ICAM)-1 [10, 11] to which the integrin binds with
the highest affinity. Even though recent studies have
shown a relationship between LFA-1 expression and the
metastatic progression [12], up to date the functional
role of this integrin in the development of liver metasta-
sis is poorly characterized.
The liver is the main organ colonized during the pro-
gression of colorectal cancer patients, where LSECs con-
stitute the first barrier cancer cells encounter and adhere
to when invading the liver, function facilitated by the
broad repertoire of adhesion molecules expressed on
their surface [2]. Among others, the cell adhesion mol-
ecule ICAM-1 is constitutively expressed on LSECs and
its expression is significantly increased during diverse in-
flammatory processes and at early stages of liver metas-
tasis [13]. Additionally, the operating mechanisms used
by immune cells to adhere to the liver endothelium and
to infiltrate the organ afterwards are unique. This
process in the liver involves different steps than those ones
reported in the classical rolling-adhesion-extravasation
paradigm. In some inflammatory scenarios, the direct ad-
hesion based on LFA-1/ICAM-1 interaction was observed
[14]. Interestingly, several solid cancers have shown a high
expression of these two molecules including pancreatic
cancer [2], and a decreased expression of LFA-1 on
lymphoma cells has been correlated with a reduced inva-
sion and metastases in vivo [15]. In line with these reports,
we showed previously that LFA-1 expression correlates
with the production of angiogenic factors by C26 cells,
such as VEGF [12], as well as with an increase in the de-
velopment of metastatic foci in the liver [12].
In addition, the local immune response developed in
the liver during tumor infiltration determines the sur-
vival of cancer cells. In this organ, liver sinusoidal
lymphocytes (LSLs) comprise the main population of
immune cells, and develop an immune response during
metastatic colonization. However, we have previously re-
ported that tumor-activated LSECs decreased the cyto-
toxic potential of these lymphocytes towards C26 cells
in vitro, mediated by the activity of mannose receptor
(ManR) expressed on LSECs [4]. Furthermore, the previ-
ous stimulation of tumor cells with soluble ICAM-1
(sICAM-1) increased the activity of ManR on LSECs
and further reduced the cytotoxic potential of LSLs once
they have interacted with tumor activated LSECs [4].
Moreover, either the ManR blockage on tumor-
stimulated LSECs or the neutralization of ManR stimu-
lating factors derived from sICAM-1 activated tumor
cells, such as Interleukin (IL)-1β inducing factors and
Cyclooxygenase (COX)-2-dependent factors, restored
the cytotoxicity of LSLs towards the cancer cells after
their interaction with tumor-activated LSECs [4].
All these data led us to hypothesize that colon carcin-
oma cells could mimic the paradigm of leukocyte re-
cruitment to the liver by means of the LFA-1/ICAM-1
pathway. Here, we assessed the effect of the reduced ex-
pression of the β2 subunit of the LFA-1 integrin during
tumor progression of C26 colon cancer cells to the liver.
Herein, we demonstrate that a decrease in LFA-1 β2 sub-
unit expression limits the retention and the migratory
potential of tumor cells in the liver and reduces the re-
cruitment of immune cells into the organ leading to a
diminution in the metastatic progression. This might be
related to the activation of an inflammatory microenvir-
onment triggered by tumor LFA-1 with endothelial
ICAM-1. Thus, our results demonstrate that the full ex-
pression of LFA-1 integrin expressed on the surface of
tumor cells facilitates the formation of liver metastasis
during C26 colon carcinoma progression by initially
driving the pro-tumoral activation of LSECs, and indu-
cing the infiltration of the liver by immune cells with
regulatory functions. These results point out LFA-1 as a
potential therapeutic target in the treatment of hepatic
metastatic disease.
Methods
Animals
Eight weeks old male Balb/c mice were obtained from
Charles River (Barcelona, Spain). Housing, care, and ex-
perimental conditions were carried out in conformity
with institutional guidelines and national and inter-
national laws for experimental animal care. The animals
were fed a standard chow and had access to water ad
libitum. All the proceedings were approved by the
Basque Country University Ethical Committee (CEID) in
accordance with institutional, national and international
guidelines regarding the protection and care of animals
use for scientific purposes.
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Cancer cell lines
All in vitro and in vivo experiments were conducted
using the murine C26 colon adenocarcinoma (C26) cell
line (also known as MCA-26, CT-26) syngenic with
Balb/c mice and purchased from ATCC (LGC Standards
S.L.U. Barcelona, Spain). The C26 cell line was genetic-
ally modified to partially deplete the expression of the β2
subunit of the LFA-1 receptor (named β2-C26) by Inno-
prot S.L. (Zamudio, Spain). The cDNA sequence corre-
sponding to Itgb2, with accession number NM:008404,
was introduced in the siDESIGNER CENT from Dhar-
macon (Lafayette, CO), and the sequences siItgb2–1:
tcggaaggtgttggataa, siItgb2–2: ggtgaaaacgtatgagaaa, and
si Itgb2–3: ctgcatgtccggaggaaat were selected. The three
sequences were cloned in the vector containing pSUper-
Purofor, a vector system for expresson of shRNA induc-
tion of Puromycin resistance (Oligoengine; WA, USA)
to produce the corresponding shRNA. The pSuper-
RNAi system provides a mammalian vector that directs
intracellular synthesis of siRNA-like transcription. The
resulting transcript of the recombinant vector is a pre-
dicted shRNA. The transcript is quickly cleaved to pro-
duce a functional siRNA. After 48 h transfection with
1 μg of each plasmid containing the sequence to obtain
either of each shRNA, the tumor cells were cultured in
the presence of puromycin (10 μg/ml) to obtain isolated
clones. In some experiments a pool of the transfected
cells were used. After 2–3 weeks of culture in the pres-
ence of puromycin 24 clones/shRNA tested were se-
lected. Then, those clones were amplified and the six
with lower expression were selected for stable lines gen-
eration. When the amount of 1,2 × 106 cells was ob-
tained, a RNA amplification for β2 integrin allowed the
selection of the clone with the lower β2 expression for
experimentation. The primers used for amplification
were Itgb2 F: ATGTGGGCCCACACTCACTGC and
Itgb2 R: TTAACAAAAGGCAGCACCGT. The clone
was cultured under standard conditions in RPM-1640
supplemented with 10% heat-inactivated fetal bovine
serum (FBS), penicillin (10,000 U/ml), streptomycin
(10.000 μg/ml) and amphotericin B (25 μg/ml) supple-
mented with 10 μg/ml Puromycin.
Culture of primary LSEC
The isolation and culture of mouse LSECs have been de-
scribed elsewhere [4, 16]. Purified LSECs were cultured
on 1 mg/ml collagen type I from rat tail – 0′25 ml/cm2−
(Sigma-Aldrich, St. Louis, MO, USA) coated tissue cul-
ture plates at a concentration of 3′5 × 105 cell/cm2 in
RPMI-1640 supplemented with 5% FBS, antibiotics and
antimycotics. LSECs were incubated at 37 °C, 5% CO2
for at least 2 h before experimental procedures. Cultures
of LSEC were pre-activated for 16 h with β2-C26 cells or
C26 cells prior to different analyses.
Cancer cell adhesion assay
Either C26 or β2-C26 cells previously labeled with
25 μM CFSE (Life Technologies Inc.; MD, USA) at 37 °C
were added to LSECs cultures or collagen type I coated
wells at a concentration of 2 × 105 cells/ml. In additional
experiments β2-C26 pool, or β2-neutralizing antibody
(1 μg/106 cells; BD Pharmingen, Madrid, Spain) pre-
treated C26 were also added to collagen type I coated
wells. After an incubation of 30 min, total fluorescence
was measured by using Ascent Fluoroskan (Labsystems
S.A.C., MA, USA). Then, fluorescence emitted by ad-
hered cells was measured after an extensive washing
with culture medium to remove non adherent cells. The
percentage of tumor cell adhesion was calculated after
background subtraction as follows:
% adhesion = (fluorescence emitted by adhered cells ×
100)/ total fluorescence.
In some experiments, tumor cells were treated with
blocking antibodies against CD11a (Clone M17/4) after
tumor cell activation with sICAM-1 before their addition
to LSECs culture. In others, tumor cells were pre-treated
with antibodies against CD11b (Clone EPR1344) and
polyclonal CD11b/c, and LSECs were pre-treated with
blocking antibodies against CD106 (VCAM-1) Clone
429, at a concentration of 1 μg/ml for 45 min, prior to
the addition of the tumor cells.
Migration and transendothelial migration assay
The migration assay was carried out on a modified Boy-
den chambers. Briefly, either C26, β2-C26 cells, β2-C26
pool, or β2-neutralizing antibody (1 μg/10
6 cells; BD
Pharmingen, Madrid, Spain) pretreated cells were seeded
onto type I collagen (1 mg/ml) -coated 8 μm-diameter
pore Transwell inserts (Greiner Bio-one, Germany) and
a total of 2 × 104 tumor cells in 100 μl of cell culture
medium supplemented with 1% FBS and antibiotics were
added to the upper chamber. In some experiments,
tumor cells were allowed to adhere and expand before
addition of sICAM-1 (200 ng/ml) (Life Technologies
Inc). Then, they were allowed to migrate for 18 h before
processing and quantification. For transendothelial mi-
gration, 2 × 105 LSECs were seeded and allowed to ad-
here and spread for 2 h before tumor cell addition.
Then, C26, β2-C26 cells were allowed to migrate and
transmigrate for 42 h, respectively, and quantified after
4% formalin fixation and crystal violet staining (Sigma-
Aldrich). Data are expressed relative to the number of
parental C26 cells migrated under basal conditions, in
both migration and transmigration studies.
Viability assay
PrestoBlue Cell Viability Reagent® (Life Technologies
Inc.) was used for quantification of viable tumor cells
following manufacturer instructions. After 3 h (time 0)
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and 48 h of culture, C26 cells and β2-C26 cells viability
was measured by adding Presto blue reagent for 90 min.
Absorbance was measure with the Ascent Multiskan
(Labsystems). Increase in cell viability after 48 h were
compared with the cell viability at time 0.
Analysis of cell cycle and number of cell divisions
A quantity of 5 × 105 C26 or β2-C26 cells were collected
and washed with PBS. After fixation in 2% formaldehyde
containing PBS, the cells were resuspended in 500 μl of
FxCycle™ PI/RNAse Solution (Life Technologies Inc.) and
incubated for 30 min. Then, differences in PI labeling were
assessed by FACS (EPICS S Elite, Beckman Coulter, Brea,
CA, USA) and analyzed using the Weasel free software
(WEHi, Parkville, VIC, Australia) with a specific cell cycle
protocol. For quantification of n° of cell divisions, tumor
cells were labeled with CFSE. Non divided cells were rep-
resented by those fixed before culturing. The remaining
cells were re-suspended to 5 × 105 cells, and cultured for
48 h. Cells were then collected and fixed and total emitted
florescence was measured by FACS and analyzed by
Weasel free with a specific CFSE protocol. The fluores-
cence emitted by these cells, fixed at time 0, is considered
to be the maximal amount of fluorescence measured in
the assay and represents those cells which have not suf-
fered any division. Thus, the number of cell cycles can be
quantified by a decrease in the fluorescence emitted by a
group of cells at a specific time point.
Endocytosis and antigen processing assay
ManR activity was measured by LSEC incubation with
FITC-labeled mannan (10 μg/ml) (Sigma-Aldrich, IL,
USA) for 2 h. The mannan uptake was quantified by As-
cent Fluoroskan (Labsystems) and expressed as the per-
centage of internalized mannan respective to total added
amount. Next, processing of DQ-ovalbumin (Life Tech-
nologies Inc.) was measured by 30 min incubation of
LSECs with the ligand. After excess of DQ-ovalbumin
was removed, its processing was quantified as the in-
crease of fluorescence respective to the Initial one.
Real time-PCR analysis
Cell lysates of C26 and β2-C26 cells were obtained after
their previous stimulation with sICAM-1. Total RNA
was extracted using PureLink® RNA Mini kit (Life Tech-
nologies Inc.), according to the manufacturer’s instruc-
tions. RNAse-free DNase I was used to prevent DNA
contamination. RNA concentration was assessed by
absorbance at 260 nm using a NANO DROP spectro-
photometer (ND-1000, Thermo Scientific, Rockford, IL),
and the purity of the samples was estimated by the OD
ratios (A260/A280, ranging within 1.8ROP2). Reverse
transcription (RT) was performed in a 20 ml reaction
volume with 2 lg of total RNA treated with 25 mM
MgCl2, PCR buffer 103, 100 mM dithiothreitol (DTT),
0.5 ll of Oligo(dt16), 50 U multiscribe reverse transcript-
ase, 40 U RNase inhibitor and 40 mM dNTP to
synthesize first-strand cDNA. Reaction system was incu-
bated at 25 °C for 10 min (primer annealing), 42 °C for
15 min (synthesis) and final temperature of 4 °C, and
resulting cDNA was stored at 220 °C. The resulting
cDNA was subjected to RT-qPCR for the evaluation of
the relative expression levels of b-actin (as an internal
control). Gene-specific amplification was performed
using ABI 7900HT, a RT-qPCR machine (Life technolo-
gies, Grand Island, NY) that measures binding of SYBR
Green I to double- stranded DNA. Each sample was
tested with a no template control for each pair of oligo-
nucleotide primers to control contamination or primer
dimer. Each experiment was repeated at least three
times using cDNA samples from separate RT reactions.
The reactions were performed in a total volume of 10 ll
that contained the following: 35 ng cDNA that was syn-
thesized as described above, 5 ll of SYBR Green master
mix (Life technologies) and 200 nM of each pair of
oligonucleotide primers. The amplification was per-
formed as follows: an initial step at 95 °C for 10 min,
followed by 45 cycles of 95 °C for 30 s and 60 °C for
60 s. Regression curves were calculated for each sample,
and the amplified sample were calculated for each from
the threshold cycles using the instrument. The following
primers for RT-PCR analyses were used:
Itgb2: forward 5′-ATGTGGGCCCACACTCACTGC-3′
and reverse 5′-TTAACAAAAGGCAGCACCGT3′;
VEGF: forward 5′-TGTACCTCCACCATGCCAAG-3′,
reverse 5′-ACTTGATCACTTCATGGGACTTCT-′3′;
COX-2: forward 5′-TGCACTATGGTTACAAAAGCT
GG-3′; reverse 5′-TCAGGAAGCTCCTTATTTCCCTT-3′.
LSLs isolation and tumor cytotoxicity assay
LSLs were obtained by means of liver perfusion with
PBS-0.1 mM EDTA and Lympholite M (Cederlane,
Canada) gradient centrifugation as previously described
[4]. For assessment of cytotoxic activity of LSLs towards
C26 cells, lymphocytes were allowed to interact with ac-
tivated and not activated LSECs for 24 h. The activation
of LSECs was induced by incubation with either C26
cells or β2-C26 cells. Then, LSLs were collected and
added to target tumor cells at a ratio of 5:1 effector/tar-
get cells. After 24 h of co-incubation, tumor cell viability
was estimated by the Presto Blue assay (Life Technolo-
gies Inc.). Data were expressed as 100- % C26 viability
respective to untreated cells.
Early retention of cancer cells in the liver and
experimental development of hepatic metastasis
For tumor cell retention and hepatic metastasis, 2 × 105
of either C26 cells or β2-C26 cells were intrasplenically
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(i.s.) injected into anesthetized mice as previously de-
scribed [4]. For retention studies, tumor cells were firstly
labeled with CFSE as described above, and mice eutha-
nized 24 h later. Livers were removed and embedded in
OCT (Tissue-Tek®, The Netherlands) and frozen in dry-
ice. For hepatic metastasis, mice were inoculated with
C26 cells, β2-C26 cells, β2-C26 pool cells or neutralizing
β2-antibody pre-treated C26 cells injected i.s. into anes-
thetized mice. Then, mice were sacrificed 14 days after
tumor cell inoculation, livers were collected, fixed in
zinc-fixative solution (Sigma-Aldrich, MO, USA) and
paraffin embedded for histological analyses after H&E
staining or embedded in OCT and frozen in dry-ice for
fluorescence immunohistochemical studies. Tumor oc-
cupied area was quantified in three10 μm thick sections
per liver, separated by 500 μm from each other. The
total tumor burden was calculated as the sum of the area
of each of the metastatic foci in 100 mm2 of liver sec-
tion. Additionally, the number of foci within a specific
size range was also calculated. At least 5 mice per group
were used per each experiment and each one was per-
formed 3 times for those experiments using the partially
silenced clone and 4 mice for those experiments using
the pool of partially depleted cells and cells pre-treated
with anti β2 integrin antibody.
Immunohistochemical analysis
Frozen liver sections were analyzed for the quantification
of different immune cell populations, 24 h and 14 days
after the tumor cell injection. The quantification of CD4+,
CD8+, CD11b+ and Ly6G+ (Gr1+) cell numbers was car-
ried out in 3 different sections per mice, and At least 5
mice per group were used per each experiment and each
one was performed 3 times. Anti-CD4 monoclonal anti-
body (Life Technologies, Inc.), anti-CD8 monoclonal anti-
body and anti-CD11b (both from Abcam; Cambridge,
UK), and anti-Ly6G antibody (Novus Biologicals; CO,
USA) were used. After blocking and incubation with spe-
cific primary antibodies, surface molecules were detected
by the use of secondary antibodies conjugated either with
Alexa-488 or Alexa-594.
Statistical analyses
Data are expressed as mean ± standard deviation (SD) of
three independent experiments. Statistical analysis was
performed using SPSS version 13.0 (Professional statistic,
IL, USA). Individual comparisons were performed using
two-tailed, unpaired Student t test. Differences were con-
sidered to be significant for *p < 0.05 and **p < 0.01.
Results
Reduced expression of β2 integrin in transfected C26 cells
A stable cell line with a reduced expression of β2 integ-
rin was established and routinely tested for the level of
β2 integrin expression at RNA level (Fig. 1a) and at pro-
tein level (Fig. 1b) by real time-PCR and western blot
analyses, respectively. Additionally, the levels of β2 integ-
rin were assessed by FACS analysis (Fig. 1c) and found
to be expression decreased in the stable C26 cell line, as
observed by FACS, RT-PCR and Western blot. Addition-
ally, the levels of β2 expression in a β2-depleted C26
pool and in cells transiently transfected with the siRNAs
were also quantified (Fig. 1d).
Reduced activity of β2 integrin on tumor cells decreases
the metastatic development in the liver
To establish the metastatic potential of β2-C26 cell, the
cells were i.s. Inoculated into Balb/c mice. A second group
of animals were inoculated with wild type C26 as control.
Either cell type induced metastasis in the liver 14 days
after inoculation (Fig. 2a). However, the colonization of
the liver by β2-C26 cells was significantly reduced compar-
ing to that of parental C26 cells. The area occupied by
tumor in the liver of mice bearing C26 cells (Fig. 2b left)
was significantly reduced. These results show the decrease
in the metastatic potential of tumor cells after the partial
depletion of β2 integrin subunit. To further confirm that
the observed reduction was not due to the absence of
clonal variability but to the depletion of the β2 integrin
subunit, additional experiments were carried out by in-
oculating a pool of stably transfected cells or C26 cells
pre-treated with β2 integrin neutralizing antibody. Under
this conditions, liver colonization was also reduced as a
result of the absence of integrin β2 (Fig. 2b right). As
shown in Fig. 2c, the various experimental conditions
where the β2 integrin subunit was depleted caused a de-
crease in the tumor burden as a result of a reduction in
the number of foci of each size.
Reduced expression of tumor β2 integrin decreases tumor
cell adhesion in vitro
LSECs are the first cell type C26 cells encounter when
entering the liver. Thus, the adhesion of tumor cells to
the endothelium is believed to constitute a limiting step
during early stages of metastatic progression. In order to
analyze the effect of a reduced expression of the β2 in-
tegrin on tumor cells in the adhesion to LSECs, we
quantified the adhesion of murine colon carcinoma cells
C26 (grey bars) and β2-C26 (white bars) cells to LSECs
(Fig. 3a). To do so, CFSE-labeled tumor cells were added
to monolayers of primary LSECs. As shown in Fig. 3a,
the reduced expression of β2 integrin diminished by 35%
the amount of tumor cells adhered to endothelial cell
monolayers. Additionally, to confirm the involvement of
LFA-1, C26 cells were treated with a neutralizing anti-
body recognizing CD11a, the αL subunit of the integrin,
prior to their addition to LSEC cultures. Cell adhesion
of C26 (grey bars) was affected by either the partial
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depletion of β2 (Fig. 3a) or the neutralization of αL sub-
unit (Fig. 3b). Interestingly, these antibodies also abo-
lished the increase observed in the adhesion of C26
tumor cells after activation by sICAM-1 (Fig. 3b). On
the contrary, no significant effect was noted when other
ICAM-1 ligands (CD11b and CD11c) were blocked on
tumor cells by neutralizing antibodies or when the lig-
and for the β1 integrin VLA-4, VCAM-1, was
neutralized on LSECs (light grey, Fig. 3c). Moreover, the
adhesion to immobilized sICAM-1 was decreased for β2-
C26 cells (Additional file 1A).
Partial deficiency in β2 integrin reduces cancer cell
migration through LSEC monolayers and collagen
Following adhesion to the endothelial cells in the sinu-
soids, tumor cells must migrate across a layer of LSECs,
Fig. 1 Analysis of the expression of β2-integrin on C26 and β2-C26 cells. Lysates of unmodified (wild type) and β2-depleted C26 cells were collected
for RNA (a) and protein (b-c) expression levels. a For β2 integrin RNA analysis by RT-PCR the following primers were used: forward ATCCTGACCCCCAA
TGATGG, reverse 5’CGGATGGGTAGTCGAACTCA. GAPDH was used as an internal control (house keeping gene) (b) Protein lysates were obtained from
1 clone cell line clones as described in Material and methods. At the protein level, the β2 integrin was detected by Western Blotting applying specific
antibodies recognizing the β2 subunit of the integrin. c Tumor cells were incubated in the presence of specific antibodies for the integrin β2. Then, cells
were subjected to FACS analysis after incubation of Alexa-488 antibody. The black line represents C26 cells, the red line represents β2-C26 cells and
dash line represents the negative control. d Protein lysates were obtained from a pool of stably transfected C26 (left). Additionally, protein lysates were
obtained from C26 tumor cells transiently transfected either with a control siRNA or three siRNAs specific for β2 integrin (right). At the protein level, the
β2 integrin was detected by Western Blotting applying specific antibodies recognizing the β2 subunit of the integrin
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and then through the extracellular matrix (ECM) in the
space of Disse, which is composed mainly by collagen
type I. To assess the role of this integrin in these pro-
cesses, we first analyzed the migratory potential of C26
cells through a monolayer of LSECs. After 42 h, a 3-fold
decrease in trans-migrated tumor cells was observed for
those with a reduced expression of β2 integrin compared
to unmodified C26 cells (Fig. 4a). Secondly, we quanti-
fied the adherence of C26, β2-C26 cells, β2-C26 pool
cells and anti-β2 pre-treated C26 cells to collagen type I
by adding the tumor cells to a layer of collagen type I.
Figure 4b left reveals a 40% reduction in the adhesive
potential of β2-C26 compared to unmodified C26 cells,
and of 30 and 45% for β2-C26 pool cells and anti-β2 pre-
treated C26 cells respectively (Fig. 4c right). In addition,
the adhesion of tumor cells, transiently transfected with
a control siRNA and three different siRNAs, to collagen
type I confirmed the siRNA 3 as the one with the high-
est silencing efficiency (Additional file 1B). Furthermore,
the pre-treatment of either C26 or β2-C26 cells with a
neutralizing antibody for β1 integrin showed no implica-
tion of this integrin in the reduction in adhesion ob-
served after depletion of β2 integrin (Additional file 1C).
Finally, the potential of C26 and β2-C26 cells to migrate
through collagen I layer was tested (Fig. 4c left). The mi-
gration of β2 deficient cells was reduced by 25% (Fig. 4c
Fig. 2 Effect of the partial deficiency of the integrin subunit β2 on C26 colon carcinoma cells on tumor metastasis to the liver. Mice were sacrificed
14 days after either C26, β2-C26 cells i.s. inoculation, and metastatic development was quantified in paraffin embedded liver sections. In some
experiments the mice were inoculated with a pool of β2-C26 cells or with C26 pre-treated with a neutralizing antibody for β2 integrin. a H&E
staining showing a reduced size of metastatic foci in animals injected with β2-C26 cells versus C26 cells. b The area of liver occupied by the
C26 cells or β2-C26 cells (left) and by C26, a pool of β2-C26 cells or by C26 pre-treated with a neutralizing antibody for β2 integrin (right). Total
tumor burden was quantified as the area occupied by the tumor per 100 mm2 of liver area. c Tumor foci were classified by their size and their
number quantified per liver tissue section. Data obtained from mice inoculated with C26 cells or β2-C26 cells are shown in the left and by
C26, a pool of β2-C26 cells or by C26 pre-treated with a neutralizing antibody for β2 integrin in the right. Data are mean values ± SD from
three different experiments (n = 15). Changes were considered statistically significant at * p < 0.05 and **p < 0.01. Scale bar 100 μm
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left). Furthermore, the addition of sICAM-1 to the cul-
tures increased 75% the number of migrated C26, while
a lack of such response was observed when β2 was par-
tially inactivated in the tumor cells activated by sICAM-
1 (Fig. 4c left). As shown for the adhesion to collagen
type I of β2-C26 cells, the pool of transfected C26 cells
with a decreased expression of β2 integrin and those
C26 cells pre-treated with neutralizing antibodies for the
for β2 subunit also showed a reduced adhesive potential
to the extracellular matrix protein (Fig. 4 right). Add-
itionally, neutralization of β2 integrin subunit in MC38
colon carcinoma showed similar effects in metastatic,
adhesive and migratory potential of the tumor cells
(Additional file 2A-C).
Partial deficiency on β2 integrin reduces proliferation in
C26 cells
In order to assess the role of β2 in the proliferation of
colon cancer cells, firstly we evaluated in vitro viability
of β2-C26 vs. C26 cells after 48-h incubation. A 2-fold
reduction was observed in the number of β2-C26 tumor
cells compared to that of unmodified C26 cells (Fig. 5a).
To verify if this resulted from an interference with the
cell cycle, we assessed the amount of cells in each phase
of the cell cycle reporting a slight, but not significant,
increase in the number of cells in G0/G1 and G2/M
and also, a slight decrease in the number of cells in S
(Fig. 5b). It is noteworthy, that cells in subG1 were in-
creased by 3-fold. Then, we quantified the number of
cycles undergone by the tumor cells within 48 h of their
culture in comparison to cells at time 0 (T0 - first red
peak) (Fig. 5c). As shown, the pattern of cell divisions
was slightly, although not significantly, altered in β2-
C26 tumor cells, since the number of cells in T3, repre-
senting those which have undergone 3 divisions, were
lower. Besides, the number of β2-C26 tumor cells that
divided only once (T1) or twice (T2) was higher than
for C26 tumor cells (Fig. 5c).
Tumor LFA-1 mediates ManR activation on LSEC
We tested ManR activation status on LSEC by means of
FITC-labeled mannan uptake, a well-known ligand of
ManR. This process is known to be altered on LSECs
Fig. 3 Modulation of the adhesive potential of C26 cells by reduced expression of β2 integrin. The ability to adhere to liver endothelial cells
(LSECs) of C26 and β2- C26 cells was tested with adhesion assays. a C26 and β2-C26 cells were added to cultures of primary isolated LSECs and
allow to adhere for 30 min before quantification of cell adhesion. b In subsequent experiments, C26 cells were pre-activated with sICAM-1
(200 ng/ml). Before sICAM-1 activation some tumor cells were pre-treated with neutralizing antibodies for the subunit αL of the integrin. c In order
to rule out other adhesion molecules present on the surface of tumor cells or LSECs, C26 cells were pre-treated either with CD11b or with
CD11b/c, and LSECs were pre-treated with VCAM-1 antibodies before the addition of tumor cells to LSEC cultures. Data are mean values ± SD
from three different experiments. Differences were considered statistically significant at *p < 0.05 and **p < 0.01
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after direct endothelial ICAM-1/tumor LFA-1 inter-
action and abolished after the binding of those two ad-
hesion molecules is blocked [4]. As shown in Fig. 6a,
while the uptake of mannan by LSECs was increased
after being co-cultured with C26 cells, no significant up-
regulation was observed when β2-C26 cells were added.
Then, the ability to process an antigen was measured by
quantifying the fluorescence emitted by degraded DQ-
ovalbumin, after its uptake by ManR expressed on LSEC
(Fig. 6b). The intracellular processing of DQ-ovalbumin
by LSECs was increased after their co-culture with wild-
type C26 but not with β2-C26 cells (Fig. 6b). Moreover,
the increase in ManR-mediated expression of Vascular
Endothelial Growth factor (VEGF) and COX-2 genes by
the tumor cells in response to sICAM-1 stimulation was
abrogated in β2-C26 cells (Fig. 6c).
LSLs cytotoxic activity towards C26 is down-modulated
by LSECs stimulated with by β2-C26
To evaluate the effects of tumor activated LSECs on the
cytotoxic activity of LSLs towards C26 cells, LSLs were co-
cultured with LSECs previously activated by cocultivation
Fig. 4 Reduced β2 integrin expression reduces migratory potential of C26 cells through LSEC, and adhesion to and migration through collagen type I.
The ability of tumor C26 and β2-C26 cells to migrate across LSEC monolayers (a), and the ability of C26 cells or β2-C26 cells (left) and that of C26, a pool
of β2-C26 cells or C26 pre-treated with a neutralizing antibody for β2 integrin (right) to adhere to a layer of collagen type I (b), and to migrate through
collagen type I (c) was quantified. Transmigration and migration studies were carried out in modified Boyden chambers. Representative pictures of C26
cells transmigrated through the LSEC are shown in a. Migrated cells are expressed as the average number of cells that migrated per 20× field. Data are
mean values ± SD from three different experiments. Differences were considered statistically significant at *p < 0.05 and *p < 0.01
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with either C26 or β2-C26 tumor cells. Then, LSLs were
collected and transferred to C26 cultures and their cyto-
toxicity towards tumor cells was assessed. As shown in
Fig. 6d, the contact of LSLs with resting LSECs increased
their cytotoxic activity towards C26 cells, however, this
cytotoxicity was reduced when LSLs were in contact
with LSECs previously activated by C26 cells. On the
contrary, the cytotoxic potential of LSLs towards tumor
cells was recovered when LSECs were activated with
β2-C26 cells (Fig. 6d).
Decreased expression of tumor LFA-1 impairs early
retention of cancer cells in the liver
The retention of cancer cells in the target organ is a
key step for the metastatic development. To quantify
retention of tumor cells in vivo, mice were i.s.
injected with tumor cells and sacrificed 24 h later. A
2-fold reduction in tumor cell numbers retained in
the liver was observed in the livers of mice injected
with β2-C26 cells (Fig. 7), in line with the previous in
vitro results.
Fig. 5 Decreased β2 expression on C26 cells modulates their proliferative activity. a Cell viability was assessed by the Presto Blue assay after 48 h of
cell culture. b Cell cycle analyses were carried out by measuring the DNA content by flow cytometry of tumor cells stained with PI. c The number of
divisions undetaken by tumor cells was quantified by CFSE assay. Control cells (C26) or β2-C26) were fixed immediately after CFSE- labeling to show
fluorescence emitted by non-divided cells (T0), that is, at time 0 before cells were allowed to divide. The remaining tumor cells were further incubated
for 48 h under normal culture conditions. Cells that underwent one cell division are gated in T1 and further constitutive numbers reflect the number
of cell divisions (T2-T3). Cells included in each gate are represented by red peaks. Fluorescence data are mean values ± SD from three different
experiments. Changes were considered statistically significant at * p < 0,05
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Fig. 6 The potential of C26 cells to activate LSECs is mediated by tumor LFA-1 expression. Uptake of TRITC-labeled mannan (a) after stimulation
with either C26 cells (grey bar) or β2-C26 cells (white bar) was quantified. Data are presented as % of internalized uptake by LSECs activated by
either C26 or β2-C26 cells compared to that of LSECs cultured alone. b The expression of genes involved in the ability of C26 to altered Mannose
receptor upregulation after ligation of LFA-1 with endothelial ICAM-1 was analyzed by quantitative PCR in tumor cell lysates after sICAM-1 (200 ng/m)
stimulation. Data of RNA expression are presented as C26 cells gene expression relative to sICAM-1 activated C26 cells gene expression (dark bars) and
β2-C26 cells gene expression relative to sICAM-1 activated β2−C26 cells gene expression (white bars). c DQ-ovalbumin processing by LSECs (short dash
line) was quantified after stimulation with either C26 cells (continuous line) or β2-C26 cells (long dash line). Data are presented as AFU -arbitrary
fluorescence units. Data are mean values ± SD from three different experiments. Changes were considered statistically significant at *p < 0.05.
d Activation of LSECs by C26 cells with partial expression of β2integrin does not affect lymphocyte cytotoxic activity towards C26. Liver sinusoidal
lymphocytes (LSLs) were incubated for 24 h with either untreated LSECs, or LSECs activated with C26 or β2-C26 cells. Then, LSLs were transferred to
C26 cultures and co-incubated for another 24 h. Subsequently, their cytotoxic activity towards C26 cells was measured by the Presto Blue assay. Basal
untreated LSLs (left bar) were used to quantify basal cytotoxic activity of LSLs towards C26 cells. Data are mean values ± SD from three different
experiments. Changes were considered statistically significant at *p < 0.05
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Decreased expression of tumor β2 integrin correlates with
a reduced recruitment of immune cells at early stages of
metastasis
Liver sections collected from mice bearing either C26 or
β2-C26 cells for 24 h were immunohistochemically ana-
lyzed, and the numbers of immune cells were quantified.
As shown in Fig. 8a, the infiltration of the liver by
CD11b+Ly6G+ cells was significantly reduced (~ 40%) as
were the numbers of CD8+ cells (30%)(Fig. 8b) in mice
injected with β2-C26 cells vs. C26 cells. At this early
stage of the metastatic disease, no significant differences
were observed in CD4-expressing cells (Fig. 8c).
Diminished expression of tumor β2 is related to a
reduced infiltration of immune cell at late stages of
metastatic progression
After 14 days of cell inoculation, the numbers of
CD11b+Ly6G+ cells were significantly increased in
tumor bearing mice comparing to the numbers observed
24 h after tumor inoculation (Fig. 9a and Additional file 3).
However, this increase was weaker (by 60%) in mice inoc-
ulated with β2-C26 cells.
Moreover, while the numbers of the CD4+cell subset
remained unchanged in the peritumoral areas surroun-
ding the tumor foci, CD4+ T cell counts increased within
the tumor foci (intra-tumoral) developed in the liver col-
lected from mice inoculated with C26 cells but not in
those tumors observed within the livers of mice bearing
β2-C26 cells (Fig. 9b and Additional file 4). Interestingly,
the numbers of CD4+ T cells in the peritumoral tissue of
livers collected in late stages of tumor progression
(Fig. 9b) were not increased when compared to those
present in the early stages of liver metastasis when
tumor cells are being retained in the liver (Fig. 8c).
Regarding to the quantification of CD8+ T cells, a de-
crease in their numbers in those tumor foci devel-
oped in mice inoculated with β2-C26 cells was
reported (Fig. 9c and Additional file 5). In contrast to
the observation made in regard to CD4+ T cell count
in peritumoral areas, CD8+ T cells count did dimin-
ished in regions surrounding the tumor foci within
livers inoculated with β2-C26 cells.
Discussion
Expression of LFA-1 (αLβ2) on lymphoid [17] and mye-
loid [18] tumor cells was demonstrated in the past, and
more recently also on solid tumors such as colorectal
cancer [4, 12]. However, the relevance of β2 integrin ex-
pression to metastatic spread of the latter tumors and
the mechanisms by which this integrin might act
through in the tumor microenvironment remain very
poorly characterized. Using a stably modified murine
colon carcinoma C26 cell line with a reduced expression
of β2 (CD18) integrin (β2-C26 cells), we show that the
reduction in functional LFA-1 decreases the metastatic
development and tumor foci size when inoculated i.s. in
mice. The β2 subunit of the integrin is needed for LFA-1
(CD11a/CD18) activity. Therefore, we aimed to investi-
gate which processes leading to formation of metastasis
were affected by a partial deficiency in β2 integrin. We
detected that the reduction in tumor generation in vivo,
observed in mice injected with β2-C26 cells, was accom-
panied by a decrease in tumor cell adhesion in vitro and
a reduced retention of tumor cells in the hepatic sinu-
soids in vivo. This uncovers an important role of tumor
LFA-1 in the modulation of the metastatic progression
of colorectal tumor cells to the liver. Interestingly, the
adhesion of C26 cells to LSEC was affected only by β2
partial deficiency or by anti-CD11a neutralization, but
not by tumor CD11b/c nor VCAM-1 blockade on
LSECs, a ligand for the integrin CD49d (α4β1), confirm-
ing a role for LFA-1 on tumor metastasis development
of colorectal cancer to the liver.
The adhesion of tumor cells to the endothelium must
be followed by the process of diapedesis across endothe-
lial cells [6, 7, 14], in order to invade parenchyma and
avoid cell death by anoikis [19]. After adhesion, the
transmigration of tumor cells across the endothelial layer
might be mediated by LFA1/ICAM-1 interaction since
the cells partially depleted in β2-integrin showed an im-
paired capacity of trans-endothelial migration. The in-
volvement of these adhesion molecules has been also
observed in the transmigration of monocytes [20] and
melanoma cells [6] through the endothelium. In fact,
stimulation of C26 cells with sCAM-1 increased their
migratory potential. The process might be promoted by
Fig. 7 β2−integrin reduced expression prevents C26 cell retention in
the liver. The retention of fluorescently labeled-C26 (grey bar) or β2-
C26 cells (white bar) in the liver was quantified 24 h after i.s. inoculation
of the tumor cells
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the contribution of ICAM-1/LFA-1 interaction to the
endothelial cell-cell separation [21]. Later on, tumor cells
must interact with the extracellular matrix and migrate
through a pathway mediated by direct contact of C26
cells with proteins which comprise this matrix [22, 23].
The reduced adhesion to and migration across collagen
type I by β2-C26, observed in these studies, is in line
with other reports linking this integrin to adhesion [24]
and transmigration of leukocytes through endothelial
cell layers [25]. Garnotel et al. [26] showed that type I
collagen induced the phosphorylation of both αL and β2
subunits of LFA-1 and that the activation of protein kinase
C as well as the stimulation of superoxide production by
polymorphonuclear neutrophils, which was abolished by
the use of neutralizing antibodies [25]. Moreover, after
activation the αLI domain favors collagen type I, the main
protein of the extracellular matrix in the tumor stroma,
when compared to collagen type IV [23]. Even though,
other integrins such as β1 might be related to the activity
of β2 integrin, we ruled out the participation in the adhe-
sion observed in β2-C26 since neutralizing antibodies
against β1 integrins could to abrogate C26 cell adhesion
nor induce a higher degree of reduction in the adhesion of
β2-C26 cells to collagen type I. In fact, the engagement of
β2 integrins is involved in polymorphonuclear neutrophils
adhesion and extravasation by maintaining an active
crosstalk with β1 integrin [27].
Additionally to their role as receptors for components
of the extracellular matrix, integrins also regulate various
cellular responses such as proliferation and loss of adhe-
sion [26, 28]. The influence of integrins in this pathway
has also been reported in a model of multiple myeloma
[29]. Here, we show that the reduction in β2 expression,
linked to the LFA-1 activity, impaired tumor cell pro-
liferation when cultured on collagen type I. Also, these
cells showed a slightly slow-down in cell division.
Schmidmaier et al. [29] observed that while the in vivo
progression of the tumor in a myeloma model was re-
lated to high rate of proliferation of LFA-1 positive
Fig. 8 The reduced expression of tumor β2 integrin limits the infiltration
of suppressor immune cells at the early stages of liver colonization.
a-c The effects of the partial deficiency of β2 integrin expression
on the recruitment of immune cell populations 24 h after i.s. tumor
cell inoculation was quantified. Immune cell subsets recruited to
the liver were immuhistochemically analyzed by labeling with specific
antibodies against CD11b and Ly6G antigens (CD11b+Ly6G+ cells) (a),
and CD8 (CD8+ T cells) (b) and CD4 (CD4+ T cells) (c) lymphocytic
markers. The quantification of CD4+, CD8+, CD11b+ and Ly6G+ (Gr1+)
cell numbers was carried out in 3 different sections per mice, and at
least 5 mice per group were used per each experiment and each one
was performed 3 times. Data are mean values ± SD from 10 different
fields/100 mm2 liver tissue section. Changes were considered statistically
significant at *p< 0.05
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tumor cells, they only detected a slight variation,
although not significant, in the levels of several cyclins
[30]. However, they observed a decrease in the survival
of cells treated with an LFA-1 inhibitor which might be
induced by an increase in p53 and p21. In agreement
with these reports, we could detect a higher number of
β2-C26 cells in sub G1. It is noteworthy that LFA-1 acti-
vation with sICAM-1 stimulates the activity of COX-2
and the increase in PGE2 production by C26 tumor cells
(Arteta et al., personal communication). The increase in
COX-2 activity in gastric adenocarcinoma has been
related to bcl-2 expression and an increase in cell sur-
vival [31]. Indeed, NS298 and celecoxib, selective
cyclooxygenase-2 inhibitors, induce apoptosis by a de-
crease in the activity of anti-apoptotic molecule bcl-2 in
LNCaP cells [32] and Akt [33] in human prostate cells.
In previous studies, we reported that the ligation of
LFA-1 expressed on tumor cells with endothelial ICAM-1
induced the production of ManR-stimulating factors from
C26 cells, including IL-1, VEGF and sICAM-1 [4, 12],
mediated by the activity of COX-2 in tumor cells. This
up-regulation of ManR activity on LSECs was related to
the inhibition of the cytotoxic activity of LSLs against the
tumor after their interaction with tumor activated LSECs
[4]. We found that β2-C26 cells were unable to increase
the activity of this endothelial receptor and, as a result, the
cytotoxic potential of LSLs towards tumor cells in vitro
was not diminished. It is interesting to note that, while
sICAM-1 stimulation of C26 cells induced the production
of ManR stimulating factors, this was abolished by pre-
treatment of tumor cells with either LFA-1 neutralizing
antibodies or the COX-2 inhibitor celecoxib (Arteta et al.,
personal communication). During the immune response
mounted to fight the tumor cells, different subpopulations
of immune cells are recruited to the organ to be colo-
nized. Among them, CD11b+ Ly6G+ cells, a subset of
myeloid derived suppressor cells (MDSCs) [34], are re-
cruited from the circulation to the liver attracted by an
array of soluble factors derived from the liver tumor
microenvironment [35]. The recruitment of CD11b+
Ly6G+ cells (granulocytic-MDSCs) in vivo was decreased
in the liver of β2-C26 bearing mice. These cells are known
to compromise antitumor immune surveillance especially
in cancer [36, 37], preventing tumor escape from the im-
mune system. Therefore, the reduced recruitment of dif-
ferent immune cell subsets found in β2-C26 bearing mice
might additionally account for the impaired metastatic
foci formation. However, if the reduced number of
CD11b+ Ly6G+ is directly linked to the partial depletion
of β2 subunit on tumor cells or to the disability of these
cells to induce production of chemoattractants by other
cell types needs further attention. Among others, hep-
atic stellate cells produce chemokines which attract
CD11b+ Ly6G+ cells to the liver [38]. Additionally,
Fig. 9 The impaired β2 expression on tumor cells correlates with the
reduced recruitment of CD11b+Ly6G+, CD4+T lymphocytes and CD8
+ T lymphocytes at late stages of C26 cells colonization of the liver.
a The recruitment of CD11b+ and Ly6G+ (a), CD4+ T cells (b) and
CD8+ T cells (c) to the liver was immuhistochemically analyzed
14 days after i.s. inoculation of C26 cells. The quantification of CD4+,
CD8+, CD11b+ and Ly6G+ (Gr1+) cell numbers was carried out in 3
different sections per mice, and at least 5 mice per group were used
per each experiment and each one was performed 3 times. Data are
mean values ± SD from 10 different fields/100 mm2 liver tissue section.
Changes were considered statistically significant at *p < 0.05 and at
least 5 mice per group were used per each experiment and each
one was performed 3 times
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hepatic stellate cells are activated within the tumor
microenvironment by C26 cells activated by sICAM-1
(Arteta et al., personal communication) which might
be a pathway modulated, as well, by the expression of
β2 integrin on tumor cells. Some reports suggest that
CD11b+ Ly6G+ might accumulate in the liver due to
tumor-derived inflammatory factors such as PGE2 of
COX-2 origin [39], VEGF [40] and IL-1β [41], re-
leased by LSECs after interacting with tumor cells via
LFA-1/ICAM-1 [4, 12]. Taking this into account, we
confirmed a significantly down-regulated expression
of VEGF and COX-2 genes in β2-C26 cells after
sICAM-1 activation, pointing their products as regula-
tors of MDSC recruitment [42]. In contrast to the
early phase, the CD11b+ Ly6G+ numbers increased
with tumor progression in both C26 and β2-C26 bear-
ing mice livers. However, this increase was signifi-
cantly lower in β2-C26 injected mice. CD11b
+ Ly6G+
were shown to block antitumor immunity by sup-
pressing CD4+ and CD8+ T cells and inducing T
regulatory cells [43]. Even though our in vitro studies
show a significant impact on the LSLs cytotoxic acti-
vity which was related to the reduced expression of
β2 on C26 cells, we could not detect any marker (e.g.
foxp3) expressed by regulatory T cells in vivo. How-
ever, we did observe a decrease in CD4+ T cell counts
at late, but not early, stages of the metastatic develop-
ment. The decrease in the inflammatory soluble fac-
tors and adhesion molecule expression, together with
the decrease in tumor cell number, may explain the
reduced immune cell counts; and overall, the lack of
a welcoming milieu for the invasion of the liver by
cancer cells when functional LFA-1 is lacking due to
the reduced expression the its β2 subunit. As men-
tioned before, the liver tumor microenvironment is a
complex network of cell-cell and cell-matrix interac-
tions in the presence of multiple soluble factors pro-
duced by the stromal, immune and tumor cells, being
any of them a possible candidate to modulate the
local immune response in the liver.
Conclusions
In summary, our data shows that β2 expression on C26
cells mediates important processes involved in tumor
progression, such as adhesion and migration, but also
the viability of cancer cells, and the regulation of the as-
sociated local immune response. This likely involves a
diminished cytotoxic response of LSLs, mediated by
endothelial ManR, whose activity, in turn, depends on
the interaction of ICAM-1 on LSEC with the tumor β2
integrin. This fact, together with the decreased produc-
tion of pro-inflammatory factors and the down-regulated
expression of suitable adhesion molecules, might
account for the development of a tumor microenvi-
ronment which impairs the immune surveillance and
promotes tumor progression. Therefore our findings in-
dicate that blockage of LFA-1 on colon cancer cells
might constitute a potential target for developing new
therapeutical drugs for cancer treatment.
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